Remdesivir Use in the Real-World Setting: An Overview of Available Evidence
In the years of Coronavirus Disease 2019 (COVID-19), various treatment options have been utilized. COVID-19 continues to circulate in the global population, and the evolution of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has posed significant challenges to the treatment a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/5/1167 |
| _version_ | 1797598074311278592 |
|---|---|
| author | Karolina Akinosoglou Emmanouil Angelos Rigopoulos Georgios Schinas Georgia Kaiafa Eleni Polyzou Stamatia Tsoupra Argyrios Tzouvelekis Charalambos Gogos Christos Savopoulos |
| author_facet | Karolina Akinosoglou Emmanouil Angelos Rigopoulos Georgios Schinas Georgia Kaiafa Eleni Polyzou Stamatia Tsoupra Argyrios Tzouvelekis Charalambos Gogos Christos Savopoulos |
| author_sort | Karolina Akinosoglou |
| collection | DOAJ |
| description | In the years of Coronavirus Disease 2019 (COVID-19), various treatment options have been utilized. COVID-19 continues to circulate in the global population, and the evolution of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has posed significant challenges to the treatment and prevention of infection. Remdesivir (RDV), an anti-viral agent with in vitro efficacy against coronaviruses, is a potent and safe treatment as suggested by a plethora of in vitro and in vivo studies and clinical trials. Emerging real-world data have confirmed its effectiveness, and there are currently datasets evaluating its efficacy and safety against SARS-CoV-2 infections in various clinical scenarios, including some that are not in the SmPC recommendations according for COVID-19 pharmacotherapy. Remdesivir increases the chance of recovery, reduces progression to severe disease, lowers mortality rates, and exhibits beneficial post-hospitalization outcomes, especially when used early in the course of the disease. Strong evidence suggests the expansion of remdesivir use in special populations (e.g., pregnancy, immunosuppression, renal impairment, transplantation, elderly and co-medicated patients) where the benefits of treatment outweigh the risk of adverse effects. In this article, we attempt to overview the available real-world data of remdesivir pharmacotherapy. With the unpredictable course of COVID-19, we need to utilize all available knowledge to bridge the gap between clinical research and clinical practice and be sufficiently prepared for the future. |
| first_indexed | 2024-03-11T03:14:15Z |
| format | Article |
| id | doaj.art-3922b4fe7e30444a880549b1aba7a161 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-11T03:14:15Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-3922b4fe7e30444a880549b1aba7a1612023-11-18T03:39:57ZengMDPI AGViruses1999-49152023-05-01155116710.3390/v15051167Remdesivir Use in the Real-World Setting: An Overview of Available EvidenceKarolina Akinosoglou0Emmanouil Angelos Rigopoulos1Georgios Schinas2Georgia Kaiafa3Eleni Polyzou4Stamatia Tsoupra5Argyrios Tzouvelekis6Charalambos Gogos7Christos Savopoulos8Division of Internal Medicine, University General Hospital of Patras, 265 04 Patras, GreeceDivision of Internal Medicine, University General Hospital of Patras, 265 04 Patras, GreeceSchool of Medicine, University of Patras, 265 04 Patras, Greece1st Medical Propedeutic Department of Internal Medicine, AHEPA, University Hospital of Thessaloniki, Aristotle University of Thessaloniki, 541 24 Thessaloniki, GreeceDivision of Internal Medicine, University General Hospital of Patras, 265 04 Patras, GreeceDivision of Internal Medicine, University General Hospital of Patras, 265 04 Patras, GreeceSchool of Medicine, University of Patras, 265 04 Patras, GreeceSchool of Medicine, University of Patras, 265 04 Patras, Greece1st Medical Propedeutic Department of Internal Medicine, AHEPA, University Hospital of Thessaloniki, Aristotle University of Thessaloniki, 541 24 Thessaloniki, GreeceIn the years of Coronavirus Disease 2019 (COVID-19), various treatment options have been utilized. COVID-19 continues to circulate in the global population, and the evolution of the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has posed significant challenges to the treatment and prevention of infection. Remdesivir (RDV), an anti-viral agent with in vitro efficacy against coronaviruses, is a potent and safe treatment as suggested by a plethora of in vitro and in vivo studies and clinical trials. Emerging real-world data have confirmed its effectiveness, and there are currently datasets evaluating its efficacy and safety against SARS-CoV-2 infections in various clinical scenarios, including some that are not in the SmPC recommendations according for COVID-19 pharmacotherapy. Remdesivir increases the chance of recovery, reduces progression to severe disease, lowers mortality rates, and exhibits beneficial post-hospitalization outcomes, especially when used early in the course of the disease. Strong evidence suggests the expansion of remdesivir use in special populations (e.g., pregnancy, immunosuppression, renal impairment, transplantation, elderly and co-medicated patients) where the benefits of treatment outweigh the risk of adverse effects. In this article, we attempt to overview the available real-world data of remdesivir pharmacotherapy. With the unpredictable course of COVID-19, we need to utilize all available knowledge to bridge the gap between clinical research and clinical practice and be sufficiently prepared for the future.https://www.mdpi.com/1999-4915/15/5/1167remdesivirVekluryCOVID-19SARS-CoV-2real-world evidencespecial populations |
| spellingShingle | Karolina Akinosoglou Emmanouil Angelos Rigopoulos Georgios Schinas Georgia Kaiafa Eleni Polyzou Stamatia Tsoupra Argyrios Tzouvelekis Charalambos Gogos Christos Savopoulos Remdesivir Use in the Real-World Setting: An Overview of Available Evidence Viruses remdesivir Veklury COVID-19 SARS-CoV-2 real-world evidence special populations |
| title | Remdesivir Use in the Real-World Setting: An Overview of Available Evidence |
| title_full | Remdesivir Use in the Real-World Setting: An Overview of Available Evidence |
| title_fullStr | Remdesivir Use in the Real-World Setting: An Overview of Available Evidence |
| title_full_unstemmed | Remdesivir Use in the Real-World Setting: An Overview of Available Evidence |
| title_short | Remdesivir Use in the Real-World Setting: An Overview of Available Evidence |
| title_sort | remdesivir use in the real world setting an overview of available evidence |
| topic | remdesivir Veklury COVID-19 SARS-CoV-2 real-world evidence special populations |
| url | https://www.mdpi.com/1999-4915/15/5/1167 |
| work_keys_str_mv | AT karolinaakinosoglou remdesiviruseintherealworldsettinganoverviewofavailableevidence AT emmanouilangelosrigopoulos remdesiviruseintherealworldsettinganoverviewofavailableevidence AT georgiosschinas remdesiviruseintherealworldsettinganoverviewofavailableevidence AT georgiakaiafa remdesiviruseintherealworldsettinganoverviewofavailableevidence AT elenipolyzou remdesiviruseintherealworldsettinganoverviewofavailableevidence AT stamatiatsoupra remdesiviruseintherealworldsettinganoverviewofavailableevidence AT argyriostzouvelekis remdesiviruseintherealworldsettinganoverviewofavailableevidence AT charalambosgogos remdesiviruseintherealworldsettinganoverviewofavailableevidence AT christossavopoulos remdesiviruseintherealworldsettinganoverviewofavailableevidence |